Participated · Equity · Jun 2026

Spot Biosystems is developing an engineered extracellular vesicle (EV) delivery platform designed to encapsulate large nucleic acid cargo and enable repeat, non-viral dosing to skeletal muscle. The company reported a peer-reviewed study in Nature Biomedical Engineering showing EV-delivered full-length dystrophin mRNA produced sustained protein expression and improved muscle function in DMD knockout mice and sustained expression without organ toxicity in non-human primates. Spot has launched an investigator-initiated first-in-human trial at Shanghai Children's Medical Center, where the first two pediatric patients demonstrated respective 1000%+ and 2000%+ increases in dystrophin after one month and functional improvement lasting up to six months after dosing cessation. The platform is positioned to overcome limitations of AAV-based approaches by supporting larger cargo and repeat dosing. Financially, Spot emerged from stealth with $40 million in venture financing from a syndicate including LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX fund, and Saltagen Ventures. The company intends to use clinical data from the IIT to inform future regulatory pathways and further clinical development for Duchenne muscular dystrophy.

Led · Equity · Mar 2026

MiroFish is presented as an AI prediction engine that extracts real-world seed information—such as breaking news, policy drafts, and financial signals—to automatically construct a parallel digital world populated by many agents that have personality, memory, and behavioral logic. The project was developed as an open-source prototype in about 10 days by founder Guo Hangjiang (GitHub ID BaiFu) and quickly reached GitHub Trending. After earlier attention for his BettaFish project, Guo relocated to Shanghai and became CEO as part of the effort to incubate MiroFish. The company received a ¥30 million investment from Chen Tianqiao of Shanda Group to support deep incubation and provide a longer-term stage. The articles report community traction on GitHub and rapid media attention but do not disclose revenue, users, or other operating metrics. Future plans beyond incubation funding were not detailed in the coverage.

Participated · Seed · Nov 2025

Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Led · Equity · Apr 2025

VOC.AI builds AI-powered customer-service solutions centered on its AI Digital Employee and flagship product Solvea, which combines generative AI, a multi-agent architecture, and an e-commerce knowledge graph. The platform delivers omnichannel, multilingual AI agents that handle complex interactions, enterprise-grade compliance (ISO 27001, SOC2, GDPR), and cross-border returns. VOC.AI employs a pay-per-actual-service-results model and provides AI Agent services to more than 100 top brands. The company emphasizes improving workforce efficiency by automating repetitive tasks so human teams can focus on higher-value work. VOC.AI plans to accelerate development of AI-enabled agents and next-generation AI capabilities while expanding localized operations in markets including North America and Japan. The company announced a $15 million funding round to support global growth and product development.

Participated · Series A · Apr 2024

Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target various types of senescent cells using its ALEMBIC™ drug discovery platform. Its lead candidate, RLS-1496, is being advanced into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company is also developing programs targeting senescent cells in pulmonary diseases, including a program for idiopathic pulmonary fibrosis (IPF) that received a substantial CIRM grant last year. Rubedo’s pipeline targets multiple therapeutic areas tied to aging biology, such as pulmonary, dermatological, oncological, neurodegenerative and fibrotic disorders. The company is led by CEO & Co‑Founder Marco Quarta with Ali Siam as Chief Business Officer and is based in Sunnyvale, California. Financially, Rubedo recently closed a $40M Series A to fund its clinical and preclinical programs. Rubedo Life Sciences develops novel senolytic small‑molecule prodrugs via its proprietary ALEMBIC drug discovery platform to selectively target pathologic senescent cells that drive age‑related diseases. The company is advancing a pharmacological regenerative program for idiopathic pulmonary fibrosis (IPF), aiming to characterize senescent lung stem and progenitor cells and to screen a library of senolytic prodrugs on IPF primary cells. Rubedo plans to nominate a lead senolytic development candidate and to develop a clinical study using a humanized IPF model. The program is supported by a $1.45M award from the California Institute for Regenerative Medicine (CIRM). Rubedo has partnered with Cedars‑Sinai for the IPF research, with Cory Hogaboam, PhD, leading the Cedars‑Sinai effort. The company is based in Sunnyvale, CA, and is led by CEO and co‑founder Marco Quarta, PhD. Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target senescent, pro-inflammatory and pro-fibrotic cell populations using its proprietary ALEMBIC™ drug discovery platform. The company’s lead programs focus on respiratory diseases with high unmet need, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Rubedo also has preclinical candidates in oncology and plans to pursue programs in neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year. Rubedo is based in Sunnyvale, California. It recently closed a seed financing to accelerate development of its clinical pipeline.